Ovid Therapeutics (United States)

Recent papers from Ovid Therapeutics (United States)

1. Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic ReplicationJournal of Medical Virology · 2026
2. Abstract 5785: RBM39 degrader anticancer activity against neuroblastoma: CDKN2A/B deletion as a biomarkerCancer Research · 2026
3. Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaBlood Advances · 2026
4. P-604. Viral Inhibition Efficacy from Lambda Carrageenan Demonstrated Against Multiple Respiratory Viral Pathogens Including Avian Influenza H5N1Open Forum Infectious Diseases · 2026
5. KCC2 Activation Reverses Neurophysiological and Behavioral Deficits in Female Rett Mice2026
6. Antisense oligonucleotides to KIF1A polymorphisms expand targets and rescue patient-derived neurons in vitroNature Communications · 2026
7. TRLS-10 a Novel Gaba Transaminase Inhibitor (Ov329) in Combination With Docetaxel Delays Metastatic Progression in a Preclinical Model of Triple-Negative Breast CancerNeuro-Oncology Advances · 2025
8. Economic Impact of an Employer-Sponsored Integrated Digital Intervention Targeting Substance Use Disorders: Return on Investment AnalysisTelemedicine Journal and e-Health · 2025
9. Pathogenic PPP2R5D variants disrupt neuronal development and neurite outgrowth in patient-derived neurons that are reversed by allele-specific knockdownHuman Genetics and Genomics Advances · 2025
10. Activation of KCC2 during development alleviates cognitive, behavioral, and neural excitability in adult CDKL5-deficient mice2025
11. Sustained Inhibition of GABA-AT by OV329 Enhances Neuronal Inhibition and Prevents Development of Benzodiazepine Refractory SeizureseNeuro · 2024
12. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trialCardiovascular Diabetology · 2024
13. Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsyNeurobiology of Disease · 2022
14. Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 yearsEpilepsia · 2022
15. Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a StudyFrontiers in Pharmacology · 2021
16. OV329, a novel highly potent γ‐aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala‐kindled ratsEpilepsia · 2021
17. Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome miceEpilepsia · 2021
18. Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem CellsCancer Research · 2021
19. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathiesThe Medicine Forum · 2021
20. Allergic response to medical products in patients with alpha-gal syndromeJournal of Thoracic and Cardiovascular Surgery · 2021